The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study on TIL for the Treatment of Advanced Solid Tumors
Official Title: A Clinical Safety and Efficacy Study on TIL for the Treatment of Advanced Solid Tumors
Study ID: NCT04967833
Brief Summary: This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with Advanced malignant solid tumors.Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Tongren Hospital Shanghai Jiao Tong University School Of Medicine., Shanghai, , China
Name: LiJun Ma
Affiliation: Tongren Hospital,Shanghai Jiao Tong University School of Medicine
Role: PRINCIPAL_INVESTIGATOR